See more : Lanzhou Zhuangyuan Pasture Co., Ltd. (1533.HK) Income Statement Analysis – Financial Results
Complete financial analysis of StageZero Life Sciences Ltd. (SZLSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of StageZero Life Sciences Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Trans Freight Containers Limited (TRANSFRE.BO) Income Statement Analysis – Financial Results
- Axiom Holdings, Inc. (AIOM) Income Statement Analysis – Financial Results
- Medpace Holdings, Inc. (MEDP) Income Statement Analysis – Financial Results
- Axita Cotton Limited (AXITA.BO) Income Statement Analysis – Financial Results
- UserWay Ltd (UWAY.TA) Income Statement Analysis – Financial Results
StageZero Life Sciences Ltd. (SZLSF)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
About StageZero Life Sciences Ltd.
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.80M | 5.07M | 4.15M | 138.70K | 185.87K | 411.67K | 1.05M | 325.81K | 2.11M | 124.08K | 281.56K | 98.73K | 193.48K | 1.09M | 1.17M | 2.19M | 2.82M | 4.60M | 1.85M | 2.91M | 151.65K | 0.65 | 0.67 | 67.91K | 0.65 |
| Cost of Revenue | 4.20M | 3.89M | 3.46M | 1.10M | 1.27M | 1.40M | 1.47M | 0.00 | 0.00 | 1.57M | 1.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -141.80K | -141.80K | 0.00 | 0.00 |
| Gross Profit | -403.75K | 1.18M | 695.56K | -960.91K | -1.08M | -992.71K | -414.70K | 325.81K | 2.11M | -1.45M | -1.65M | 98.73K | 193.48K | 1.09M | 1.17M | 2.19M | 2.82M | 4.60M | 1.85M | 2.91M | 151.65K | 141.80K | 141.80K | 67.91K | 0.65 |
| Gross Profit Ratio | -10.64% | 23.23% | 16.75% | -692.78% | -580.67% | -241.14% | -39.34% | 100.00% | 100.00% | -1,169.11% | -587.77% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 21,802,500.00% | 21,247,000.00% | 100.00% | 100.00% |
| Research & Development | 351.99K | 774.54K | 218.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.57M | 682.11K | 517.45K | 1.40M | 2.23M | 8.37M | 8.99M | 8.17M | 5.07M | 4.57M | 2.58M | 754.27K | 873.73K | 155.14K | 155.14K | 0.00 |
| General & Administrative | 5.91M | 6.98M | 4.02M | 4.18M | 3.29M | 4.17M | 3.85M | 2.77M | 3.38M | 2.36M | 3.17M | 2.76M | 2.10M | 2.66M | 3.19M | 3.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 746.41K | 1.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 401.75K | 822.96K | 1.14M | 363.36K | 38.40K | 168.98K | 436.49K | 383.54K | 0.83 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.65M | 8.22M | 4.02M | 4.18M | 3.29M | 4.17M | 3.85M | 3.18M | 4.21M | 3.50M | 3.53M | 2.80M | 2.27M | 3.09M | 3.58M | 3.16M | 2.25M | 1.92M | 1.64M | 664.79K | 278.95K | 386.37K | 91.59K | 27.96K | 6.80K |
| Other Expenses | 338.88K | 311.34K | 29.67K | 27.29K | 12.33K | 1.46M | 107.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 219.14K | -115.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 7.34M | 9.31M | 4.05M | 4.18M | 3.29M | 4.17M | 3.85M | 3.18M | 4.21M | 5.25M | 4.66M | 3.84M | 4.44M | 6.00M | 12.28M | 12.60M | 10.79M | 7.37M | 6.58M | 3.24M | 1.03M | 1.40M | 246.73K | 27.96K | 6.80K |
| Cost & Expenses | 11.54M | 13.20M | 7.51M | 5.28M | 4.55M | 5.57M | 5.32M | 3.18M | 4.21M | 5.25M | 4.66M | 3.84M | 4.44M | 6.00M | 12.28M | 12.60M | 10.79M | 7.37M | 6.58M | 3.24M | 1.03M | 1.26M | 246.73K | 27.96K | 6.80K |
| Interest Income | 0.00 | 0.00 | 35.09K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.66K | 45.65K | 12.90K | 23.37K | 9.30K | 15.17K | 170.56K | 830.34K | 384.52K | 152.09K | 63.47K | 71.56K | 13.42K | 127.68K | 127.68K | 0.00 | 623.05 |
| Interest Expense | 284.07K | 200.31K | 320.42K | 803.20K | 1.13M | 225.70K | 472.59K | 44.60K | 5.20K | 1.23M | 714.12K | 671.76K | 586.89K | 454.09K | 99.05K | 31.80K | 16.95K | 30.41K | 13.09K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 420.11K | 308.35K | 268.48K | 305.02K | 294.96K | 359.88K | 337.64K | 4.27K | 15.54K | 275.62K | 444.70K | 521.24K | 780.29K | 675.23K | 999.10K | 956.18K | 713.61K | 658.58K | 629.16K | 289.18K | 108.74K | 141.80K | 141.80K | 0.00 | 0.00 |
| EBITDA | -10.27M | -7.62M | -6.26M | -2.44M | -2.66M | -2.25M | -4.66M | -5.99M | -6.93M | -5.50M | -3.92M | -3.20M | -3.29M | -4.21M | -9.59M | -9.46M | -7.26M | -2.11M | -4.09M | -46.73K | -772.84K | -1.12M | -1.12M | -246.73K | -6.80K |
| EBITDA Ratio | -270.62% | -150.38% | -83.88% | -3,471.32% | -2,175.81% | -862.15% | -441.64% | -873.62% | -97.97% | -4,429.44% | -1,392.50% | -3,237.01% | -1,788.74% | -384.89% | -865.70% | -431.97% | -257.78% | -45.92% | -221.01% | -1.61% | -509.63% | -171,940,311.53% | -36,968,789.34% | 58.83% | -1,044,799.47% |
| Operating Income | -7.75M | -8.13M | -3.70M | -5.11M | -4.36M | -3.90M | -4.26M | -6.04M | -6.61M | -7.12M | -4.38M | -3.72M | -4.25M | -4.90M | -11.11M | -10.41M | -7.97M | -2.77M | -4.72M | -335.91K | -881.57K | -1.26M | -246.73K | 39.95K | -6.80K |
| Operating Income Ratio | -204.13% | -160.43% | -89.09% | -3,686.23% | -2,343.03% | -946.53% | -404.56% | -1,855.13% | -313.00% | -5,737.72% | -1,555.03% | -3,764.94% | -2,196.84% | -447.98% | -951.21% | -475.65% | -283.11% | -60.25% | -254.97% | -11.56% | -581.33% | -193,742,712.99% | -36,968,789.34% | 58.83% | -1,044,799.47% |
| Total Other Income/Expenses | -3.67M | 479.23K | -3.16M | 1.41M | 662.39K | 2.21M | -1.65M | -3.24M | -4.75M | -2.00M | -696.78K | -648.38K | -383.66K | -439.95K | 259.05K | 650.25K | 224.70K | 136.98K | 34.82K | 0.00 | 0.00 | 452.45K | 0.00 | 99.40K | 6.80K |
| Income Before Tax | -11.42M | -7.48M | -6.86M | -3.48M | -3.94M | -2.95M | -5.91M | -6.09M | -6.61M | -8.83M | -5.08M | -4.39M | -4.81M | -5.34M | -10.89M | -10.53M | -8.03M | 0.00 | 0.00 | 0.00 | 0.00 | -807.65K | 0.00 | -147.33K | 0.00 |
| Income Before Tax Ratio | -300.79% | -147.67% | -165.32% | -2,510.24% | -2,121.82% | -715.96% | -560.76% | -1,868.82% | -312.89% | -7,119.98% | -1,804.08% | -4,445.32% | -2,488.45% | -488.19% | -932.46% | -480.91% | -285.21% | 0.00% | 0.00% | 0.00% | 0.00% | -124,177,154.67% | 0.00% | -216.96% | 0.00% |
| Income Tax Expense | 0.00 | 200.31K | 320.42K | 830.49K | 1.14M | 1.69M | -88.66K | -71.98K | 5.20K | 540.60K | 12.90K | 0.00 | 586.89K | 454.09K | -71.51K | -798.54K | -367.57K | -121.68K | -50.38K | -71.56K | -13.42K | -127.68K | 246.73K | -2.82K | 6.18K |
| Net Income | -11.42M | -7.68M | -7.18M | -4.31M | -3.94M | -2.95M | -5.91M | -6.02M | -6.61M | -8.83M | -5.08M | -4.39M | -4.81M | -5.34M | -10.82M | -9.73M | -7.67M | -2.65M | -4.67M | -264.35K | -868.15K | -1.13M | -246.73K | -144.51K | -6.18K |
| Net Income Ratio | -300.79% | -151.62% | -173.04% | -3,108.99% | -2,121.82% | -715.96% | -560.76% | -1,846.73% | -312.89% | -7,119.98% | -1,804.08% | -4,445.32% | -2,488.45% | -488.19% | -926.34% | -444.43% | -272.16% | -57.60% | -252.25% | -9.10% | -572.48% | -174,111,211.67% | -36,968,889.34% | -212.80% | -949,199.51% |
| EPS | -0.11 | -0.11 | -0.16 | -0.16 | -0.23 | -0.24 | -0.72 | -0.90 | -1.12 | -2.07 | -2.23 | -2.34 | -3.11 | -4.02 | -8.74 | -7.89 | -7.03 | -3.02 | -5.94 | -0.44 | -1.75 | -3.32 | -1.28 | -3.61 | -0.15 |
| EPS Diluted | -0.11 | -0.11 | -0.16 | -0.16 | -0.23 | -0.24 | -0.72 | -0.90 | -1.12 | -2.07 | -2.23 | -2.34 | -3.11 | -4.02 | -8.74 | -7.89 | -7.03 | -3.02 | -5.94 | -0.44 | -1.75 | -3.32 | -1.28 | -3.61 | -0.15 |
| Weighted Avg Shares Out | 99.43M | 70.72M | 44.82M | 26.50M | 17.11M | 12.08M | 8.22M | 6.68M | 5.92M | 4.26M | 2.28M | 1.88M | 1.55M | 1.33M | 1.24M | 1.23M | 1.09M | 875.95K | 787.04K | 605.66K | 496.99K | 341.47K | 192.75K | 40.00K | 40.00K |
| Weighted Avg Shares Out (Dil) | 99.43M | 70.72M | 44.82M | 26.50M | 17.11M | 12.08M | 8.22M | 6.68M | 5.92M | 4.26M | 2.28M | 1.88M | 1.55M | 1.33M | 1.24M | 1.23M | 1.09M | 875.95K | 787.04K | 605.66K | 496.99K | 341.47K | 192.75K | 40.00K | 40.00K |
StageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials Under the Failure To File Cease Trade Order
TORONTO, ON / ACCESSWIRE / July 9, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA gene expression multi-cancer diagnostic for screening for multiple, key cancers from...
StageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials under the Failure to File Cease Trade Order
TORONTO, ON / ACCESSWIRE / July 3, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA gene expression multi-cancer diagnostic for screening for multiple, key cancers from...
StageZero Life Sciences Ltd. (SZLSF) Q1 2024 Earnings Call Transcript
StageZero Life Sciences Ltd. (OTCQB:SZLSF) Q1 2024 Results Conference Call May 21, 2024 8:00 AM ET Company Participants Rebecca Greco - Head Investor Relations James Howard Tripp - Chairman & Chief Executive Officer Operator Good morning everyone, and welcome to...
StageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational Update
TORONTO, ON / ACCESSWIRE / May 17, 2024 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of...
StageZero Life Sciences Provides an Update on Application for Management Cease Trade Order
TORONTO, ON / ACCESSWIRE / April 5, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample...
StageZero Life Sciences Announces Delay to Fourth Quarter and Year End 2023 Financial Results
TORONTO, ON / ACCESSWIRE / April 2, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample...
StageZero Life Sciences, Ltd Announces Q3 2023 Financial Results and Operational Update
TORONTO, ON / ACCESSWIRE / November 15, 2023 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of...
StageZero Life Sciences Partners with My One Medical Source and 1,000+ Medical Access Points in the USA
Aristotle and AVRT to be offered to My One Medical Source's Customer Base TORONTO, ON / ACCESSWIRE / November 14, 2023 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only...
StageZero Life Sciences' Clinical Business Introduces Fourth Pillar to Cancer Offerings
Care Oncology Partners with WellnessScript to Offer Mental Health support to cancer patients TORONTO, ON / ACCESSWIRE / November 7, 2023 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the...
StageZero Life Sciences' Clinical Business Introduces Third Pillar to Cancer Offerings
CareOncology partners with The Source Functional Nutrition to offer nutritional guidance to cancer patients. TORONTO, ON / ACCESSWIRE / October 20, 2023 / StageZero Life Sciences, Ltd.
Source: https://incomestatements.info
Category: Stock Reports